

# A Multi-Method Approach to Modeling COVID-19 Disease Dynamics in the United States

Amir Mokhtari (✉ [mokhtari\\_amir@bah.com](mailto:mokhtari_amir@bah.com))

Booz Allen Hamilton (United States)

Cameron Mineo

Booz Allen Hamilton (United States)

Jeffrey Kriseman

Booz Allen Hamilton (United States)

Pedro Kremer

Booz Allen Hamilton (United States)

Lauren Neal

Booz Allen Hamilton (United States)

John Larson

Booz Allen Hamilton (United States)

---

## Research Article

**Keywords:** granular examination, hospitalizations, virtual laboratory to investigate

**Posted Date:** March 24th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-334277/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

1 A multi-method approach to modeling COVID-19 disease dynamics in the United States

2  
3 Amir Mokhtari<sup>\*1</sup>, Cameron Mineo<sup>1</sup>, Jeffrey Kriseman<sup>1</sup>, Pedro Kremer<sup>1</sup>, Lauren Neal<sup>1</sup>, John Larson<sup>1</sup>

4  
5 <sup>1</sup> Booz Allen Hamilton

6 \*Corresponding author: [mokhtari\\_amir@bah.com](mailto:mokhtari_amir@bah.com)

7 Address: 4747 Bethesda Ave., Bethesda, MD, 20814, USA

8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 **Abstract**

31 In this paper, we proposed a multi-method modeling approach to community-level COVID-19  
32 disease spread. Our methodology was composed of interconnected age-stratified system  
33 dynamics models in an agent-based modeling framework that allowed for a granular examination  
34 of the scale and severity of disease spread including metrics such as infection cases, deaths,  
35 hospitalizations, and ICU usage. Model parameters were calibrated using an optimization  
36 technique with an objective function to minimize error associated with the cumulative cases of  
37 COVID-19 during a training period between March 15 and October 31, 2020. We outlined  
38 several case studies to demonstrate the model's state- and local-level projection capabilities. We  
39 further demonstrated how model outcomes could be used to assess perceived levels of COVID-  
40 19 risk across different localities using a multi-criteria decision analysis framework. The model's  
41 two, three, and four week out-of-sample projection errors varied on a state-by-state basis, and  
42 generally increased as the out-of-sample projection period was extended. Additionally, the error  
43 in the state-level projections was generally due to an underestimation of cases and an  
44 overestimation of deaths. The proposed modeling approach can be used as a virtual laboratory to  
45 investigate a wide range of what-if scenarios and easily adapted to future high-consequence  
46 public health threats.

47

## 48 **Introduction**

49 During the recent COVID-19 pandemic, global efforts have taken place to contain the spread of  
50 the virus and develop effective non-therapeutic (e.g., social distancing, partial and full  
51 lockdowns) and therapeutic treatments (e.g., vaccination). As we watched the COVID-19  
52 pandemic unfold since early 2020 across the globe, researchers have identified gaps in data and  
53 our understanding of ways in which the disease has spread within and between communities  
54 including its potential impacts on general and at-risk populations<sup>1,2</sup>.

55 Computational modeling has been long employed to further increase our understanding of  
56 complex infectious diseases as well as their development, spread dynamics, and potential  
57 treatments<sup>3</sup>. Using computational modeling, we have been able to identify common patterns in  
58 infectious diseases allowing us to leverage lessons learned historically by investigating past  
59 widespread disease events to predict who may get infected, where vaccination efforts should be  
60 prioritized, and how to limit the spread of infectious diseases in future events<sup>4,5,6,7</sup>.

61 Two methods, System Dynamics (SD) and Agent-Based Modeling (ABM), have been  
62 frequently used in recent years to investigate the complex nature of infectious diseases and their  
63 potential containment strategies. SD has a long history of being applied to the study of infectious  
64 disease epidemiology. This method operates at a high level of abstraction by compartmentalizing  
65 the population into different disease stages such as Susceptible (S), Infected (I), and Recovered  
66 (R), among others while assuming population homogeneity within each compartment<sup>8,9</sup>.

67 Previous studies have identified limitations of SD in modeling infectious diseases such as  
68 inability to model multi-strain infections, deterministic nature, inability to model time-varying  
69 infectivity, and assumptions regarding population homogeneity, among others<sup>10</sup>. With the boom  
70 in computer processing capability in the 21<sup>st</sup> century, ABM has been recently used in modeling

71 infectious disease dynamics<sup>11,12</sup>. ABM uses a bottom-up approach, where a complex dynamic  
72 system is described as interacting objects with their own behaviors such that system behavior can  
73 potentially emerge as a summary of the individual actions of agents<sup>13,14</sup>. ABM for infectious  
74 diseases focuses on incorporating individual information such as personal interactions,  
75 movements, and health information in an attempt to provide a more granular profile of disease  
76 spread as compared to the homogenous population of SD models. However, ABM is not without  
77 its limitations: (1) model parameters (e.g., reproduction number for infectious diseases) are often  
78 difficult to quantify; (2) model validation can be difficult to assess, particularly when modeling  
79 unobserved associations<sup>15</sup>; (3) ABM can become exceedingly computationally intensive when  
80 applied to large populations<sup>16</sup>; and (4) lack of individualized data may result in increased model  
81 assumptions and uncertainty<sup>17</sup>.

82 In this paper, we propose a multi-method, also known as hybrid, modeling approach to  
83 community-level infectious disease spread. The idea of multi-method modeling is to integrate  
84 different methods of computational modeling to overcome the limitations of individual methods  
85 and get the most from each one<sup>18, 19, 20</sup>. Our Multi-Method Community Disease Risk Model,  
86 hereafter referred to as M<sup>2</sup>-CDRM, combines the advantages of SD and ABM, allowing the  
87 simulation of spatially explicit scenarios representing future states of disease transmission within  
88 different communities and testing risk management policies across a wide range of scenarios  
89 using “what-if” analysis. The model integrates multiple layers of data including population  
90 demographics, observed cases of illness and death, and hospital demands at the local county-  
91 level within different states to make location-specific predictions about COVID-19 illness and  
92 death. M<sup>2</sup>-CDRM can be used as a virtual laboratory to: (1) identify “hot spots” of potential  
93 areas (e.g., counties) with highest levels of infected individuals within the United States that can

94 potentially act as infection hubs during the ongoing pandemic; (2) examine population-specific  
95 characteristics (e.g., gender, age) that can result in disproportionate distribution of mortality and  
96 morbidity in cases across the United States; (3) prioritize counties based on their perceived  
97 disease risks considering multiple decision criteria; and (4) evaluate the effectiveness of  
98 candidate mitigation options (e.g., social distancing, wide-spread testing) aimed at reducing the  
99 likelihood of disease transmission within different communities. This paper outlines a case study  
100 of our proposed approach focused on modeling COVID-19 at a community level in the United  
101 States. Additionally, we introduced an example of how this model could be potentially used in  
102 conjunction with a Multi-Criteria Decision Analysis (MCDA) framework to assess and prioritize  
103 different communities in terms of their perceived risk of COVID-19.

## 104 **Methods**

105 **Model overview.** We developed M<sup>2</sup>-CDRM as a highly customizable, evidence-based, and  
106 data-driven model by integrating SD modeling approach within an ABM framework to study the  
107 COVID-19 transmission on multiple levels of aggregation in the United States (**Fig. 1**). The  
108 model is implemented using AnyLogic (Professional Edition, Version: 8.5.2, Link:  
109 <https://www.anylogic.com>), a modelling framework that integrates support for SD, ABM, and  
110 other dynamic computational methods. M<sup>2</sup>-CDRM included all 50 states as well as their  
111 individual counties with a simulation period between March 15 and December 31<sup>st</sup>, 2020.

112 **Disease transmission models.** With COVID-19, different subpopulations have been shown  
113 to be more or less susceptible, more or less likely to be infectious, and more or less likely to  
114 recover from the disease<sup>21, 22, 23</sup>. Therefore, treating the entire population with the same static  
115 assumptions about these rates can cause decision makers to miss key aspects of the disease's

116 likely trajectory. M<sup>2</sup>-CDRM addresses this limitation by including five separate SD models to  
 117 simulate COVID-19 disease dynamics in distinct age cohorts within each individual county: 0-  
 118 17, 18-44, 45-64, 65-74, and 75+ years of age. While these cohorts were initially selected to  
 119 stratify the population based on their ages, the model design is quite flexible and can  
 120 accommodate any age stratification. Each SD model was defined using eight compartments,  
 121 including Susceptible (S), Exposed (E), Asymptomatic Infection (AI), Mild Infection (MI),  
 122 Severe Infection (SI), Critical Infection (CI), Recovered (R), and Death (D). In each model,  
 123 severe infection and critical infection represented general admission to the hospital as well as  
 124 ICU admission, respectively. For each state, the spread of COVID-19 in county  $j$  and for age  
 125 cohort  $i$  was modeled based on the following set of differential equations:

$$126 \quad \frac{dS_{i,j}}{dt} = - \frac{S_{i,j} \times \sum_{l=1}^5 (I_{l,j} + AI_{l,j})}{S_j(0) - D_j} \times \frac{RE_{t,j}}{API_i} \quad (1)$$

$$127 \quad \frac{dE_{i,j}}{dt} = \frac{S_{i,j} \times \sum_{l=1}^5 (I_{l,j} + AI_{l,j})}{S_j(0) - D_j} \times \frac{RE_{t,j}}{API_i} - \frac{E_{i,j}}{IP} \quad (2)$$

$$128 \quad \frac{dI_{i,j}}{dt} = (1 - FR_{AI}) \times \frac{E_{i,j}}{IP} - \frac{I_{i,j}}{MIP_H} \times \frac{HR_i}{URF} - \frac{I_{i,j}}{MIP} \times (1 - \frac{HR_i}{URF}) \quad (3)$$

$$129 \quad \frac{dAI_{i,j}}{dt} = FR_{AI} \times \frac{E_{i,j}}{IP} - \frac{AI_{i,j}}{AIP} \quad (4)$$

$$130 \quad \frac{dH_{i,j}}{dt} = \frac{I_{i,j}}{MIP_H} \times \frac{HR_i}{URF} - \frac{H_{i,j}}{SIP_{ICU}} \times CR_i - \frac{H_{i,j}}{SIP} \times (1 - CR_i) \quad (5)$$

$$131 \quad \frac{dC_{i,j}}{dt} = \frac{H_{i,j}}{SIP_{ICU}} \times CR_i - \frac{C_{i,j}}{CIP_D} \times FR_i - \frac{C_{i,j}}{CIP} \times (1 - FR_i) \quad (6)$$

$$132 \quad \frac{dD_{i,j}}{dt} = \frac{C_{i,j}}{CIP_D} \times FR_i \quad (7)$$

$$133 \quad \frac{dR_{i,j}}{dt} = \frac{I_{i,j}}{MIP} \times (1 - \frac{HR_i}{URF}) + \frac{AI_{i,j}}{AIP} + \frac{H_{i,j}}{SIP} \times (1 - CR_i) + \frac{C_{i,j}}{CIP} \times (1 - FR_i) \quad (8)$$

$$134 \quad API_i = \frac{1}{\frac{1}{MIP} \times (1 - \frac{HR_i}{URF}) + \frac{1}{MIP_H} \times (\frac{HR_i}{URF})} \times (1 - FR_{AI}) + AIP \times FR_{AI} \quad (9)$$

135 Where,  $S_{i,j}$  represents susceptible population in age cohort  $i$  ( $i = 1, \dots, 5$ ) in county  $j$ ,  $S_j(0)$   
 136 represents initial susceptible population in county  $j$  across all age cohorts,  $E_{i,j}$  represents exposed

137 population in age cohort  $i$  in county  $j$ ,  $I_{i,j}$  represents symptomatic infectious population in age  
138 cohort  $i$  in county,  $AI_{i,j}$  represents asymptomatic infectious population in age cohort  $i$  in county  $j$ ,  
139  $H_{i,j}$  represents hospitalized population (severe infection) in age cohort  $i$  in county  $j$ ,  $C_{i,j}$  represents  
140 critically infected population (ICU admission) in age cohort  $i$  in county  $j$ ,  $R_{i,j}$  represents  
141 recovered (non-infectious) population in age cohort  $i$  in county  $j$ ,  $D_{i,j}$  represents deceased  
142 population in age cohort  $i$  in county  $j$ ,  $IP$  represents incubation period (days),  $FR_{AI}$  represents  
143 fraction of asymptomatic population,  $MIP_H$  represents duration of mild infection prior to  
144 hospitalization (days),  $MIP$  represents duration of mild infection prior to recovery (days),  $AIP$   
145 represents duration of asymptomatic infection (days),  $HR_i$  represents hospitalization rate for age  
146 cohort  $i$  ( $i = 1, \dots, 5$ ),  $URF$  represents under-reporting factor of symptomatic infections,  $SIP_{ICU}$   
147 represents severe infection period prior to transfer to ICU (days),  $SIP$  represents severe infection  
148 period prior to recovery (days),  $CR_i$  represents critical infection rate in age cohort  $i$  ( $i = 1, \dots, 5$ ),  
149  $CIP_D$  represents critical infection period prior to death (days),  $CIP$  represents critical infection  
150 period prior to recovery (days),  $FR_i$  represents fatality rate in age cohort  $i$  ( $i = 1, \dots, 5$ ),  $API_i$   
151 represents average period of infectiousness in age cohort  $i$  ( $i = 1, \dots, 5$ ), and  $RE_{t,j}$  represents  
152 effective reproduction number at time  $t$  in county  $j$ .

153 **ABM framework to connect SD models.** Within each county, we defined population age  
154 cohorts (0-17, 18-44, 45-64, 65-74, 75+) as individual agents. Each of these individual agents  
155 was then coupled with all other agents within the same county with explicit interactivity patterns.  
156 By focusing on micro-level interactions, this framework was able to explain emergent patterns  
157 such as transient dynamics on a system level and identify important mechanisms, taking into  
158 account heterogeneity of entities (e.g., individual age cohorts as agents) and spatial and temporal  
159 heterogeneity of processes (e.g., variability in disease dynamics across different counties).

160 Additionally, the ABM structure allowed for the possibility of advanced data inputs such as age-  
161 specific reproduction numbers, interaction, and mobility patterns across age cohorts and  
162 counties, county- and age-specific adherence to social distancing policies, and what-if analysis  
163 such as customizable vaccine distribution networks. Outputs from our framework were  
164 timeseries of system-level variables further stratified by age cohorts, counties and states: (1)  
165 number of infected; (2) number of hospitalized; (3) number of ICU admissions; (4) number of  
166 deaths; and (5) hospital utilization considering available general and ICU beds in different  
167 counties.

168 **Effective reproduction number.** Since a population will rarely be totally susceptible to an  
169 infection in the real world, the effective reproduction number,  $RE_t$ , and not the basic  
170 reproduction number,  $R_0$ , should be used as a measure of disease transmissibility at time  $t^{24}$ .  $RE_t$   
171 represents the expected number of new infections caused by an infectious individual in a  
172 population where some individuals may no longer be susceptible. Estimates of  $RE_t$  are typically  
173 used to assess how changes in policy, population immunity, and population behaviors, among  
174 other factors, have affected transmission at specific point in time<sup>25, 26, 27, 28</sup>.

175 Using observed number of daily cases of COVID-19 in county  $j$ , we calculated timeseries of  $RE_{t,j}$   
176 based on the methodology discussed in Cori *et al.* and implemented in the R-package *EpiEstim*<sup>29</sup>.  
177 This package implements a Bayesian approach for quantifying transmissibility over time during  
178 an epidemic and reports a 95% confidence interval for  $RE_t$ . More specifically, it allows  
179 estimating the instantaneous and case reproduction numbers during an epidemic for which a  
180 timeseries of incidence is available and the distribution of the serial interval (time between  
181 symptoms onset in a primary case and symptoms onset in secondary case) is more or less

182 precisely known. To calculate  $RE_{t,j}$ , we assumed the median, mean, and standard deviation of the  
183 serial interval were 4.0, 4.7, and 2.9 days, respectively<sup>30</sup>.  $RE_{t,j}$  was calculated as:

$$184 \quad RE_{t,j} = \begin{cases} RE_{t,j}^*; t_{0,j} \leq t \leq t_{EC,j} \\ \max(0.3, \exp(\beta_{0,j} + \beta_{1,j} \times t)); t > t_{EC,j} \end{cases} \quad (10)$$

185 Where,  $t_{0,j}$  represents time associated with the first observed case of illness in county  $j$ ,  $t_{EC,j}$   
186 represents time associated with the end of model calibration period in county  $j$  (i.e., the last date  
187 with observed case of illness), and  $RE_{t,j}^*$  represents output from the *EpiEstim* package.  $\beta_{0,j}$  and  
188  $\beta_{1,j}$  are coefficients from fitting an exponential regression model to the estimated  $RE_{t,j}^*$  values in  
189 the last two weeks, assuming that  $RE_{t,j}^*$  continue the same trend observed in the past two weeks.  
190 The minimum value of 0.3 represents the estimated reproduction number in the City of Wuhan  
191 after the lockdown of the region<sup>25</sup>.

192 **Calibration of Model Parameters.** Model calibration is the process of identifying the model  
193 parameter configurations that best explain the observed real-time values (e.g., observed cases of  
194 illness). While simple models with fewer parameters can be potentially calibrated by manually  
195 adjusting parameter values, calibration of complex models, such as M<sup>2</sup>-CDRM, requires  
196 extensive computational effort and resources. We used a simulation-based “optimization”  
197 method to calibrate selected model parameters to estimate their values and plausible ranges such  
198 that the model outcomes would closely match existing historic data such as number of observed  
199 cases of illness.

200 The optimization engine in AnyLogic automatically finds the best values for different model  
201 parameters with respect to certain pre-defined constraints and requirements using the OptQuest

202 Engine that incorporates metaheuristics to guide its search algorithm toward better solutions<sup>31</sup>.  
203 Inputs selected for model calibration including their ranges of plausible values are listed in **Table**  
204 **1**. We performed the model calibration at both state and individual county levels by matching the  
205 number of reported cases of COVID-19 with model predictions, while defining constraints with  
206 respect to the expected number of deaths in the state (or individual counties). Considering  
207 October 31<sup>st</sup>, 2020 as the model training end date, we used a weighted L<sub>1</sub> norm equation as:

$$208 \quad d(\mathbf{X}, \mathbf{Y}) = \frac{\sum_{i=1}^T \alpha^{T-i} |X_i - Y_i|}{\sum_{i=1}^T \alpha^{T-i} \times X_i} \quad (11)$$

209 Where,  $\mathbf{Y} = \{Y_i\}$  ( $i = 1, \dots, T$ ) is the target timeseries until day T (i.e., October 31<sup>st</sup>, 2020),  $\mathbf{X} =$   
210  $\{X_i\}$  ( $i = 1, \dots, T$ ) is the model output (i.e., number of cases of illness) and  $\alpha$  is the decay factor.  
211 We used  $\alpha = 0.4$  in the model optimization as reported by Venkatramanan *et al.*<sup>32</sup>.

212 **Multi-criteria framework for prioritizing counties based on the perceived risk of**  
213 **COVID-19.** We used an MCDA framework to generate risk maps for individual states  
214 highlighting counties where surveillance and disease control measures could be potentially  
215 targeted based on the perceived levels of COVID-19 risks. The methodological steps required in  
216 our MCDA approach encompassed: (i) selection of decision criteria; (ii) definition of criterion  
217 measures; (iii) definition of scores assigned to each decision criterion representing low (1),  
218 medium (3), and high (9) perceived levels of risk; (iv) attribution of weights to decision criteria  
219 and (v) aggregation of risk scores across all selected decision criteria to generate the spatial maps  
220 for perceived levels of risk in each state.

221 Decision criteria, measures, and risk scores for ranking individual counties in each state are  
222 provided in **Table 2** and briefly discussed in the following.

- 223 • *New daily cases (NDC)*: this criterion, comparable to incidence in epidemiology represents  
224 the incident number of COVID-19 in a community. We considered a three-day average of the  
225 predicted new cases (across all age cohorts) and a cut-off value of less than *five* new cases per  
226 100,000 residents to score this criterion. A risk score of low (1), medium (3), or high (9) was  
227 assigned to this criterion in each county if the cut-off value was met within 21 days since the  
228 training end date (October 31<sup>st</sup>, 2020), after 21 days since the training end date but before the  
229 end of the simulation period (December 31<sup>st</sup>, 2020), or was never met during the simulation  
230 period, respectively.
- 231 • *Decline in new daily deaths (NDD)*: we assumed that a county must experience a sustained  
232 decline in the three-day rolling average of predicted daily hospital deaths over the course of a  
233 21-day period to be considered low risk. Alternatively, counties that have seen few COVID  
234 cases overall would satisfy this metric if the three-day rolling average of daily new hospital  
235 deaths has never exceeded one. We used three-day average of the projected number of deaths  
236 across all age cohorts in each county and scored the county as low (1), medium (3), or high  
237 (9) if the cut-off value was met within 21 days since the training end date, after 21 days since  
238 the training end date but before the end of the simulation period, or was never met during the  
239 simulation period, respectively.
- 240 • *New hospitalizations (NH)*: In addition to monitoring the decline in disease trajectory, it is  
241 important to monitor the absolute level of infection in each county. It is possible for a county  
242 that has seen a high level of infections to see a sustained decline in hospitalizations and  
243 deaths over a 21-day period still having an underlying infection rate that is too high. Using  
244 the total number of projected new hospitalization cases across all age cohorts, each county  
245 needed to have fewer than two new hospitalizations per 100,000 residents to be considered

246 low risk. We used three-day average of the projected number of new hospitalizations across  
247 all age cohorts in each county and scored the county as low (1), medium (3), or high (9) if the  
248 cut-off value was met within 21 days since the training end date, after 21 days since the  
249 training end date but before the end of the simulation period, or was never met during the  
250 simulation period, respectively.

251 • *ICU bed utilization (BU)*: It is critical that regional healthcare systems have sufficient  
252 capacity for ICU beds. Taking into account the projected number of critically infected  
253 patients in each county across all ages and the ICU bed capacity in each county, we scored  
254 each county as low (1), medium (3), or high (9) if the cut-off value of 50% was met within 21  
255 days since the training end date, after 21 days since the training end date but before the end of  
256 the simulation period, or was never met during the simulation period, respectively.

257 To simplify the scoring approach, we assigned equal weights to selected decision criteria and  
258 calculated aggregate risk scores across all decision criteria for different counties ( $RS_i$ ):

$$259 \quad RS_i = NDC_i + NDD_i + NH_i + BU_i \quad (12)$$

260 **Summary of the model inputs.** Data used in M<sup>2</sup>-CDRM came from a variety of sources,  
261 grouped into three categories of disease impact, demographic data, and hospital resources.

262 Summary data used in the model, including data sources is listed in **Table 3**.

## 263 **Results**

264 **State-Level Predictions.** **Tables 4** and **5** summarize the model predictions for number of  
265 COVID-19 cases aggregated across all age cohorts in the top 20 populous states in the United  
266 States. We reported a range of values for two-week (November 14, 2020), three-week

267 (November 21, 2020), and four-week (November 28, 2020) out-of-sample model predictions  
268 based on the 95% confidence intervals reported for  $RE_t$ . We also reported the cumulative  
269 observed values for COVID-19 cases by selected dates and % error calculated by comparing the  
270 observed values with mean predictions. For each of these states, selected model parameters  
271 (listed in **Table 1**) were calibrated to replicate observed cumulative number of cases between  
272 March 15 and October 31, 2020 across the whole state. We further used the state-wide calibrated  
273 model parameters for all individual counties in the selected state assuming no change in disease  
274 epidemiology in different localities (e.g., no change in critical infection rate for a particular age  
275 cohort across different counties in California). Summary results typically showed underestimated  
276 number of COVID-19 cases with variability in % error across different states. Furthermore, we  
277 observed relative decrease in model accuracy when period of out-of-sample predictions was  
278 increased from two to four weeks. For example, average % error for two-week out-of-sample  
279 prediction of cases was -6.7% across all 20 states with a range of values between -1.1%  
280 (California) and -16.9% (Michigan). We observed lower accuracy for the four-week out-of-  
281 sample case predictions with an average % error value of -16.2% across all 20 states and a range  
282 of values between -7.1% and -32.4% for California and Michigan, respectively. Model results  
283 showed similar patterns for predicted number of COVID-19 deaths across these selected states  
284 (**Table 5**); however, the prediction accuracies were typically higher for cumulative number of  
285 deaths by selected dates. For example, average % error for two-week out-of-sample prediction of  
286 deaths across selected states was 3.2% (compared to -6.7% error for prediction of cases) with a  
287 range of values between 0.1% and 15.2% for Missouri and Washington, respectively.

288 **County-level predictions.** For each of the state-level predictions listed in **Tables 4** and **5**, our  
289 model generated results for each individual county within a state, allowing for analysis of the

290 heterogenous disease growth patterns across localities. Although each county used an  
291 independent predicted timeseries for  $RE_t$  based on the county-specific observed cases of illness, a  
292 simplifying assumption was made that calibrated disease parameters (listed in **Table 1**) were  
293 homogenous across all counties in a particular state when model was trained to replicate the  
294 state-level observed cumulative number of cases and deaths between March 15, 2020 – October  
295 31, 2020. We further investigated the impact of this assumption on the model prediction  
296 accuracy by conducting a county-level calibration experiment across three localities in Virginia,  
297 including Richmond City, Montgomery County, and Norfolk City. The experiment included two  
298 scenarios to evaluate the out-of-sample model prediction accuracy between November 1 and 28  
299 based on: (1) calibrated model parameters using state-level observed data (223,568 and 3,973 for  
300 observed cumulative cases of illness and deaths in Virginia, respectively); and (2) county-level  
301 calibrated model parameters based on the county-specific observed data (6606, 3884, and 6423  
302 for observed cases and 82, 15, and 89 for observed deaths in Richmond City, Montgomery  
303 County, and Norfolk City, respectively).

304 **Fig. 2** shows the resulting timeseries for the out-of-sample model predictions between November  
305 1 and 28, 2020 for selected localities in Virginia including cumulative number of observed  
306 COVID-19 cases during the same time period. Each predicted timeseries represents model  
307 results for the cumulative COVID-19 cases based on the mean  $RE_t$  value as well as range of  
308 cases based on the 95% confidence interval associated with  $RE_t$  (shaded areas). Results indicated  
309 that conducting county-level model calibration led to increase in model accuracy. For example,  
310 % errors for four-week out-of-sample predictions were -11.3%, -15.4%, and -8.4% for Richmond  
311 City, Montgomery County, and Norfolk City, respectively, when model parameters were  
312 calibrated using state-level cumulative number of observed cases. When model parameters were

313 calibrated for each individual county, % errors reduced to -6.9%, -7.8%, and -4.0% for the  
314 selected counties.

315 **State-level risk maps using MCDA.** In addition to out-of-sample case and death predictions  
316 across different localities in individual states, we utilized various county-level model outputs,  
317 including three-day rolling average of new daily cases per 100,000 residents, three-day rolling  
318 average of daily new hospital deaths, three-day rolling average of new hospitalizations per  
319 100,000 residents, and ICU bed utilization percentages, and time to meet their cut-off values  
320 (listed in **Table 2**) to score individual counties with respect to their perceived levels of COVID-  
321 19 risks. Examples of model outputs for selected decision criteria are shown in **Fig. 3**, **Fig. 4**,  
322 **Fig. 5**, and **Fig. 6** for four localities in Virginia, including Charlottesville City, Hampton City,  
323 Portsmouth City, and Spotsylvania County. Model results typically showed substantial  
324 variability in number of days required to achieve the scoring requirements for selected decision  
325 criteria since the training end date (October 31, 2020). For example, for the counties that have  
326 not met the criterion requirement before October 31, number of days to achieve a three-day  
327 rolling average of new cases per 100,000 residents of five or less was 59.7 days on average with  
328 a minimum value of only two days for Norton City while 85 out of 133 counties (64%) did not  
329 satisfy this requirement by the end of the model simulation time of December 31, 2020 (data not  
330 shown here).

331 We also calculated the aggregated risk scores across selected decision criteria for all counties in  
332 Virginia. The risk map for based on the aggregated scores is shown in **Fig. 7**. Aggregated risk  
333 scores showed spatial variability with an average value of 14.3 across all counties and minimum  
334 and maximum values of 4 and 30, respectively. The model typically predicted higher aggregated  
335 risk scores (15 or higher) in the southwestern localities while lower scores (15 or lower) in the

336 northern and eastern localities of the state, primarily due to additional hospital resources (e.g.,  
337 number of general and ICU beds) in those counties.

## 338 **Discussion**

339 The COVID-19 pandemic has resulted in a global health crisis with unprecedented growing  
340 economic, social, and health impacts not seen since the 1918 Spanish flu pandemic.  
341 Computational models have played an important role in the ongoing crisis by providing insights  
342 regarding the disease spread dynamics as well as the potential impacts of public policies at the  
343 local, national, and global levels. Different models with a wide range of underlying  
344 methodologies have been used by policy makers and public health officials to assess the  
345 evolution of the COVID-19 pandemic, design and analyze control measures, and study various  
346 what-if scenarios. For example, the Centers for Disease Control and Prevention (CDC) has been  
347 working with different partners to bring together weekly COVID-19 forecasts based on statistical  
348 and mathematical models aiming to predict national and state numbers of new and total COVID-  
349 19 deaths as well as cases of infection and hospitalization<sup>33</sup>. **Table 6** provides a summary of  
350 selected COVID-19 computational models available from the CDC website including their key  
351 features, geographic scope, methodology, frequency of updates, and ability to conduct what-if  
352 scenario analysis. The majority of these models have adapted different forms of the SD-based  
353 models (e.g., SEIR) with geographical scopes typically limited to the national or state level  
354 predictions. All models faced challenges due to availability of data, rapidly evolving pandemic  
355 and unprecedented control measures put in place. Despite these challenges, we believe that  
356 mathematical models can provide useful and timely information to the policy makers.

357 Like other computational modeling methods, commonly used SD-based models can be especially  
358 useful when invoked for the right task, however they are not appropriate for all forecasting,  
359 prediction, and scenario simulations. These models operate at an elevated level of abstraction,  
360 assume population homogeneity, and typically lack the ability to update underlying model  
361 parameters once new, real-time data become available. In this study, we developed a multi-  
362 method modeling approach by using an ABM framework to combine thousands of age-stratified  
363 and location-specific SEIR models that could potentially capture the essential virus transmission  
364 dynamics for the purpose of modeling COVID-19 spread over time and in different localities  
365 with increased model fidelity. The proposed simulation model showed potential to be used by  
366 decision makers as an effective virtual laboratory in performing what-if analysis and quantifying  
367 perceive levels of health risks by combining forecasted outcomes from user-defined health  
368 metrics in a multi-criteria decision framework. While the current case study focused on COVID-  
369 19, the modular framework of our solution easily allows future adaptation to any high-  
370 consequence public health threats.

371 We have also addressed some of the limitations of the SD-based epidemiological models around  
372 key areas. First, current SD-based epidemiological models typically approximate the spread of  
373 COVID-19 at the state and national level. These models do not account for the effect of  
374 mitigation policies, population demographics, as well as cohort behaviors on the disease spread  
375 dynamics at local levels. Our multi-method approach provided enhanced precision and fidelity at  
376 the local level. Second, existing SD-based models typically focus on constant value of the basic  
377 reproduction number ( $R_0$ ) as a measure of disease transmissibility. We used potential changes in  
378  $R_0$  over time, represented by  $R_E$ , which reflected how the disease transmission within the  
379 population changed over time. We used this dynamic adjustment to assess how changes in

380 mitigation policies, population immunity, and population behaviors, among other factors, could  
381 potentially affect COVID-19 transmission at specific time and location points. Lastly, most SD-  
382 based models fail to account for the effect of population demographics (e.g., age), particularly at  
383 the county and local levels. We believe that characterizing model parameters such as disease  
384 transmission, hospitalization, critical infection, and fatality rates based on the population  
385 demographics potentially mitigates the bias for under-represented segments of the population.

386 We are also aware that computational models are approximations of the real-life scenarios. There  
387 are currently no predictive models that generate a highly accurate picture of the COVID-19  
388 disease spread or its clinical impacts, including ours, as too many factors can potentially affect  
389 the spread of the disease. For example, our models showed to underestimate cases and  
390 overestimate deaths. Modelling exercises tend to carry forward certain distortions that are  
391 inherent to the complex and dynamic characteristics of reporting systems when it comes to fast  
392 evolving epidemiological scenarios. In the case of COVID-19, certain factors in relation to a sub-  
393 optimal standardization in the coding and reporting of potential, suspected, and confirmed cases  
394 might have introduced information biases in “real-life” that generate mismatches with the model  
395 outcomes. A similar phenomenon could have taken place in terms of inaccuracies regarding  
396 causes of deaths and the role of COVID-19 in death certificates.

397 There are also areas for improvement in our modeling approach that can enhance the prediction  
398 accuracy. For example, the current approach for calibrating the model parameters is largely an  
399 ad-hoc simulation-based procedure based on the state-level observed cases of infection as well as  
400 death. Although computationally intensive, we demonstrated that the model accuracy could be  
401 substantially improved when calibrations were conducted at the local levels (e.g., individual  
402 counties). Also, while we used observed daily cases of COVID-19 to characterize location-

403 specific timeseries for  $R_E$ , future values were approximated using exponential regression models  
404 fitted to the latest two weeks of data. This approximation may potentially pose bias and  
405 limitations in forecasting the disease dynamics in populous areas where changes in behaviors  
406 (e.g., lack of social distancing, limited stay-at-home restrictions) can significantly impact the  
407 disease spread trajectory. We understand that recent studies have demonstrated promising use of  
408 novel forecasting methodologies to characterize relationships between human micro-level  
409 activities and movements based on telemetry data and micro-level  $R_E$  values<sup>34,35,36</sup>. Such  
410 methodologies can be potentially coupled with our modeling approach. Lastly, we did not  
411 estimate age-stratified timeseries for  $R_E$  because reported daily cases of COVID-19 currently do  
412 not contain demographic data including age. Accounting for heterogeneity in transmission due to  
413 demographic factors and also estimating age-stratified reproduction numbers could provide  
414 insight into differences in transmission potential by age and other factors. In addition, although  
415 the use of age serves as proxy of several risk factors and health conditions, subsequent  
416 improvements of this modeling approach could account for other epidemiological and  
417 demographic population characteristics that are highly correlated with COVID-19 transmission  
418 and outcomes. This is the case for co-morbidities, mobility patterns, population density, and  
419 climate, among others. Finally, our model relies on the current body of evidence with regards to  
420 the chances of reinfection. In this sense, recovered patients are considered to be immune to  
421 future COVID-19 infections. These assumptions are being revised as new viral variants are  
422 identified, which might imply the need to redefine the basic assumptions of the model. Taking all  
423 these aspects into consideration could result in interventions that are more effectively targeted to  
424 reduce the size of an outbreak in different localities, even as an outbreak is unfolding.

425

426 **REFERENCES**

- 427 1. Lang, T. Plug COVID-19 research gaps in detection, prevention and care. *Nature* **583**, 333  
428 (2020).
- 429 2. Bhatia, R., Sledge, I. & Baral, S. The missing science: Epidemiological data gaps for  
430 COVID-19 policy in the United States. *medRxiv*, doi:  
431 <https://doi.org/10.1101/2021.02.11.21251602> (2021).
- 432 3. Jenner, A.L., Aogo, R.A., Davis, C.L., Smith, A.M. & Craig, M. Leveraging computational  
433 modeling to understand infectious diseases. *Curr. Pathobiol. Rep.* **8**, 149-161 (2020).
- 434 4. Kok, S. *et al.* Optimizing an HIV testing program using a system dynamics model of the  
435 continuum of care. *Health Care Manag. Sci.*, **18**(3), 334-362 (2015).
- 436 5. Thompson, K.M., Duintjer Tebbens, R.J., Pallansch, M. A., Wassilak, S. G. & Cochi, S. L.  
437 Polio eradicators use integrated analytical models to make better decisions. *Interfaces*, **45**(1),  
438 5-25 (2015).
- 439 6. Sharareh, N., Sabounchi, N.S., Sayama, H. & MacDonald, R. The Ebola crisis and the  
440 corresponding public behavior: A system dynamics approach. *PLoS currents* **8**,  
441 doi: [10.1371/currents.outbreaks.23badd9821870a002fa86bef6893c01d](https://doi.org/10.1371/currents.outbreaks.23badd9821870a002fa86bef6893c01d) (2016).
- 442 7. van Ackere, A. & Schulz, P.J. Explaining vaccination decisions: A system dynamics model  
443 of the interaction between epidemiological and behavioral factors. *Socio-Econ. Plan. Sci.* **71**,  
444 100750 (2020).
- 445 8. Anderson, R. M. & May, R. M. *Infectious diseases of humans: dynamics and control* (Oxford  
446 University Press, 1991).
- 447 9. Keeling, M. J. & Rohani, P. *Modeling infectious diseases in humans and animals* (Princeton  
448 University Press, 2011).

- 449 10. Roberts, M., Andreasen, V., Lloyd, A. & Pellis, L. Nine challenges for deterministic  
450 epidemic models. *Epidemics* **10**, 49-53 (2015).
- 451 11. Merler, S. *et al.* Spatiotemporal spread of the 2014 outbreak of Ebola virus disease in Liberia  
452 and the effectiveness of non-pharmaceutical interventions: a computational modelling  
453 analysis. *Lancet Infect. Dis.* **15**(2), 204-211 (2015).
- 454 12. Crooks, A.T. & Hailegiorgis, A.B. An agent-based modeling approach applied to the spread  
455 of cholera. *Environ. Modell. Softw.* **62**, 164-177 (2014).
- 456 13. Macal, C.M. & North, M. J. (2005). Tutorial on agent-based modeling and simulation.  
457 *Proceedings of the Winter Simulation Conference, IEEE.*  
458 <https://doi.org/10.1109/WSC.2005.1574234> (2005).
- 459 14. Crooks, A. T. & Heppenstall, A. J. *In Agent-based models of geographical systems:*  
460 *Introduction to agent-based modelling* (Springer, Dordrecht, 2012).
- 461 15. Midgley, D., Marks, R. & Kunchamwar, D. Building and assurance of agent-based models:  
462 An example and challenge to the field. *J. Bus. Res.* **60**(8), 884-893 (2007).
- 463 16. Bonabeau, E. Agent-based modeling: methods and techniques for simulating human systems.  
464 *PNAS* **99**(3), 7280-7287 (2002).
- 465 17. Frias-Martinez, E., Williamson, G. & Frias-Martinez, V. An agent-based model of epidemic  
466 spread using human mobility and social network information. In *2011 IEEE 3<sup>rd</sup> international*  
467 *conference on privacy, security, risk and trust and 2011 IEEE third international conference*  
468 *on social computing*, IEEE. <https://doi.org/10.1109/PASSAT/SocialCom.2011.142> (2011).
- 469 18. Li, Y., Zhang, Y. & Cao, L. Evaluation and selection of hospital layout based on an  
470 integrated simulation method. *WSC*, 2560-2568 (2020).

- 471 19. Brailsford, S.C. Hybrid simulation in healthcare: New concepts and new tools. *WSC*, 1645-  
472 1653 (2015).
- 473 20. Viana, J. Reflections on two approaches to hybrid simulation in healthcare. *WSC*, 1585-1596  
474 (2014).
- 475 21. Vaughan, L. *et al.* Relationship of socio-demographics, comorbidities, symptoms and  
476 healthcare access with early COVID-19 presentation and disease severity. *BMC Infect.*  
477 *Dis.* **21**(1), 1-10 (2021).
- 478 22. Davies, N.G. *et al.* Age-dependent effects in the transmission and control of COVID-19  
479 epidemics. *Nat Med* **26**, 1205–1211 (2020).
- 480 23. Lau, M. S. *et al.* Characterizing superspreading events and age-specific infectiousness of  
481 SARS-CoV-2 transmission in Georgia, USA. *PNAS*, **117**(36), 22430-22435 (2020).
- 482 24. Gostic, K.M. *et al.* Practical considerations for measuring the effective reproductive number,  
483  $R_t$ . *medRxiv* doi: <https://doi.org/10.1101/2020.06.18.20134858> (2020).
- 484 25. Pan, A. *et al.* Association of public health interventions with the epidemiology of the  
485 COVID-19 outbreak in Wuhan, China. *JAMA* **323**(19), 1915-1923 (2020).
- 486 26. Kucharski, A.J. *et al.* Early dynamics of transmission and control of COVID-19: a  
487 mathematical modeling study. *Infect. Dis.* **20**(5), 553-558 (2020).
- 488 27. Cauchemez, S., Kiem, C.T., Paireau, J., Rolland, P. & Fontanet, A. Lockdown impact on  
489 COVID-19 epidemics in regions across metropolitan France. *Lancet* **396**(10257), 1068-1069  
490 (2020).
- 491 28. Flaxman, S. *et al.* Estimating the effects of non-pharmaceutical interventions on COVID-19  
492 in Europe. *Nature* **584**, 257-261 (2020).

- 493 29. Cori, A., Ferguson, N.M., Fraser, C. & Cauchemez, S. A new framework and software to  
494 estimate time- varying reproduction numbers during epidemics. *Am. J. Epidemiol* **178**(9),  
495 1505-1512 (2013).
- 496 30. Nishiura, H. Correcting the actual reproduction number: a simple method of estimating R0  
497 from early epidemic growth data. *Int. J. Environ. Res. Public Health* **7**, 291-302 (2020).
- 498 31. Laguna, M. *Optimization of Complex Systems with OptQuest*. Graduate School of Business,  
499 University of Colorado (1997).
- 500 32. Venkatramanan, S. *et al.* Using data-driven agent-based models for forecasting emerging  
501 infectious diseases. *Epidemics* **22**, 43-49 (2018).
- 502 33. Center for Disease Control and Prevention (CDC). Interpretation of forecasts of new and  
503 total deaths <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/forecasting-us.html>  
504 (2021).
- 505 34. Rudiger, S. *et al.* Forecasting the SARS-CoV-2 effective reproduction number using bulk  
506 contact data from mobile phones. *medRxiv* doi: <https://doi.org/10.1101/2020.10.02.20188136>  
507 (2020).
- 508 35. Linka, K., Goriely, A. & Kuhl, E. Global and local mobility as a barometer for COVID-19  
509 dynamics. *medRxiv* doi: <https://doi.org/10.1101/2020.06.13.20130658> (2020).
- 510 36. Leung, K., Wu, J.T. & Leung G.M. Real-time tracking and prediction of COVID-19  
511 infection using digital proxies of population mobility and mixing. *medRxiv* doi:  
512 <https://doi.org/10.1101/2020.10.17.20214155> (2020).

**Table 1.** Parameters used in model calibration and their plausible range of values

<b>Model Parameter</b>	<b>Description</b>	<b>Range of Values</b>
MIP	Mild infection period prior to recovery (days)	2 - 14
MIP <sub>H</sub>	Mild infection period prior to hospitalization (days)	2 - 14
IP	Incubation period (days)	1 - 14
CR	Critical infection rates for different age cohorts (%) <sup>a</sup>	1 - 95
URF	Under-reporting factor	1 - 10

<sup>a</sup> Constraints were defined for critical infection rates for different age cohorts as:

$$CR_{0-17} < CR_{18-44} < CR_{45-64} < CR_{65-74} < CR_{75+}$$

**Table 2.** Decision criteria, measures, and risk scores for ranking individual counties in each state

Decision Criterion	Criterion Measure	Criterion Risk Scores		
		Low (1)	Medium (3)	High (9)
Three-day rolling average of new cases	< 5/100K population	Criterion met within 21 days since the training end date	Criterion met before the end of the simulation	Criterion not met before the end of the simulation
Three-day rolling average of new deaths	< 1			
Three-day rolling average of new hospitalizations	< 2/100K population			
ICU bed utilization	< 50%			

**Table 3.** Data used in M<sup>2</sup>-CDRM including their sources

<b>Data Element</b>	<b>Data Application</b>	<b>Reference</b>
<b>Disease impact</b>		
Number of observed daily cases in different counties	Compared to predicted number of cases in different counties during the model calibration step	USA Facts: <a href="https://usafacts.org">https://usafacts.org</a>
Number of daily deaths in different counties	Used as constraints during model calibration based on the observed vases of illness in different counties	USA Facts: <a href="https://usafacts.org">https://usafacts.org</a>
<b>Demographic data</b>		
County-level population density and age distribution	Used to initialize the compartmental models for selected age cohorts	Census Bureau: <a href="https://www.census.gov/programs-surveys/decennial-census/data/datasets.2010.html">https://www.census.gov/programs-surveys/decennial-census/data/datasets.2010.html</a>
<b>Hospital resources</b>		
Age-specific hospitalization rates	Used in the disease transmission model for each age cohort	CDC: <a href="https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html#hospitalizations">https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html#hospitalizations</a>
Number of general and ICU beds	Numbers of general and ICU beds adjusted by the available occupancy rates were used to calculate ICU and hospital utilization rates in different counties. Once ICU capacity is reached in a county, new patients in need of ICU admission would be transferred to the deceased population compartment ( $D_{i,j}$ )	Centers for Medicare & Medicaid Services' Healthcare Cost Report Information System (HCRIS): <a href="https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Cost-Report">https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Cost-Report</a>
Hospital occupancy rates	State-level acute care and critical access hospital occupancy rates in urban vs rural areas were used to adjust number of available general and ICU beds available in each county	American hospitals directory: <a href="https://www.ahd.com/news/HFM_DataTrends_2018_July.pdf">https://www.ahd.com/news/HFM_DataTrends_2018_July.pdf</a>

**Table 4.** Model performance for two-, three-, and four-week out-of-sample predictions of the cumulative COVID-19 cases in the top 20 populous states

State	Two-Week Out-Of-Sample Predictions (November 14, 2020)			Three-Week Out-Of-Sample Predictions (November 21, 2020)			Four-Week Out-Of-Sample Predictions (November 28, 2020)		
	Range of Predictions	Observed	% Error	Range of Predictions	Observed	% Error	Range of Predictions	Observed	% Error
California	964,486 - 1,017,792	990,096	-1.1%	991,330 - 1,101,984	1,053,945	-3.3%	1,021,323 - 1,211,919	1,147,417	-7.1%
Texas	927,085 - 1,044,511	984,377	-3.0%	944,996 - 1,152,937	1,050,255	-5.0%	963,036 - 1,275,089	1,128,131	-7.6%
Florida	819,518 - 844,319	852,174	-2.7%	836,321 - 882,500	897,322	-4.9%	853,484 - 927,956	953,300	-7.7%
New York	515,129 - 543,158	536,214	-2.3%	521,856 - 573,152	568,847	-5.6%	528,035 - 608,774	607,070	-9.4%
Pennsylvania	215,722 - 232,495	238,657	-7.0%	223,702 - 254,648	275,513	-14.9%	231,659 - 281,377	321,070	-22.7%
Illinois	419,938 - 459,360	511,169	-15.2%	436,352 - 508,202	597,818	-23.0%	452,833 - 565,200	674,072	-27.5%
Ohio	221,957 - 242,352	261,483	-12.1%	230,590 - 267,693	305,365	-20.1%	239,068 - 297,812	371,908	-30.3%
Georgia	347,637 - 370,294	376,032	-5.8%	351,721 - 391,865	391,429	-7.4%	355,332 - 416,164	408,643	-9.3%
North Carolina	278,608 - 295,263	297,973	-4.4%	284,890 - 314,174	316,955	-6.9%	290,521 - 334,812	343,408	-11.0%
Michigan	195,442 - 218,456	245,252	-16.9%	204,300 - 246,177	296,840	-26.3%	213,149 - 279,695	347,746	-32.4%
New Jersey	245,806 - 255,510	260,430	-4.1%	253,457 - 271,881	285,519	-8.7%	261,572 - 292,107	313,863	-13.1%
Virginia	184,386 - 197,766	194,906	-3.0%	187,695 - 210,732	206,751	-5.5%	190,612 - 224,668	223,568	-9.9%
Washington	108,774 - 115,661	120,011	-7.5%	110,811 - 123,182	134,118	-14.6%	112,670 - 131,872	151,018	-21.9%
Arizona	249,274 - 255,512	263,133	-4.3%	253,739 - 265,544	279,896	-7.8%	258,348 - 277,724	306,868	-13.6%
Massachusetts	168,537 - 179,938	180,753	-4.9%	173,406 - 198,166	197,561	-9.0%	178,620 - 224,517	214,874	-11.9%
Tennessee	268,495 - 293,014	289,749	-4.2%	279,257 - 322,714	320,729	-7.9%	289,913 - 356,839	345,853	-9.0%
Indiana	186,156 - 203,048	222,186	-13.3%	193,852 - 224,421	265,099	-22.6%	201,574 - 250,066	309,503	-29.3%
Missouri	190,799 - 207,726	220,768	-10.6%	198,389 - 228,183	253,473	-17.3%	205,381 - 250,666	282,792	-21.6%
Maryland	148,742 - 159,294	156,709	-2.9%	151,885 - 170,824	169,804	-7.1%	154,884 - 184,520	185,464	-11.8%
Wisconsin	256,093 - 279,759	293,812	-9.5%	275,475 - 320,478	342,155	-14.2%	295,568 - 369,722	386,441	-16.1%

**Table 5.** Model performance for two-, three-, and four-week out-of-sample predictions of the cumulative COVID-19 deaths in the top 20 populous states

State	Two-Week Out-Of-Sample Predictions (November 14, 2020)			Three-Week Out-Of-Sample Predictions (November 21, 2020)			Four-Week Out-Of-Sample Predictions (November 28, 2020)		
	Range of Predictions	Observed	% Error	Range of Predictions	Observed	% Error	Range of Predictions	Observed	% Error
California	18,684 - 19,020	18,069	4.0%	19,211 - 20,055	18,356	6.0%	19,737 - 21,493	18,876	6.9%
Texas	18,973 - 19,734	18,850	1.9%	19,516 - 21,245	19,680	1.5%	19,959 - 23,236	20,736	0.3%
Florida	16,925 - 17,049	17,248	-1.5%	17,295 - 17,586	17,643	-1.3%	17,659 - 18,202	18,157	-1.6%
New York	32,652 - 33,326	33,486	-1.7%	33,296 - 34,747	33,690	0.4%	33,867 - 36,471	33,961	2.2%
Pennsylvania	10,176 - 10,387	9,086	13.0%	10,630 - 11,088	9,355	15.6%	11,070 - 11,919	9,951	14.5%
Illinois	10,301 - 10,613	10,289	1.3%	10,824 - 11,511	10,874	1.9%	11,317 - 12,585	11,677	0.9%
Ohio	5,575 - 5,696	5,547	1.4%	5,858 - 6,117	5,742	3.8%	6,142 - 6,618	6,118	3.3%
Georgia	8,276 - 8,403	8,259	0.8%	8,444 - 8,740	8,481	0.5%	8,577 - 9,129	8,641	1.3%
North Carolina	4,202 - 4,279	4,638	-8.9%	4,368 - 4,517	4,719	-6.4%	4,516 - 4,780	5,039	-8.4%
Michigan	8,457 - 8,765	8,093	6.0%	8,950 - 9,635	8,510	8.1%	9,415 - 10,677	9,094	8.6%
New Jersey	17,227 - 17,434	16,461	5.2%	17,713 - 18,155	16,618	7.7%	18,204 - 19,027	16,819	10.2%
Virginia	3,991 - 4,057	3,717	7.9%	4,138 - 4,305	3,827	9.9%	4,276 - 4,558	3,973	10.1%
Washington	2,836 - 2,888	2,479	15.2%	2,925 - 3,043	2,566	15.8%	2,999 - 3,222	2,680	14.7%
Arizona	6,021 - 6,069	6,192	-2.4%	6,130 - 6,235	6,312	-2.2%	6,238 - 6,435	6,513	-3.1%
Massachusetts	11,279 - 11,526	10,184	11.6%	11,588 - 12,189	10,360	13.7%	11,907 - 13,181	10,551	16.3%
Tennessee	3,884 - 3,975	3,670	6.9%	4,080 - 4,275	3,994	3.8%	4,272 - 4,629	4,372	1.0%
Indiana	4,856 - 4,959	4,731	3.7%	5,112 - 5,329	5,024	3.5%	5,356 - 5,756	5,435	1.5%
Missouri	3,287 - 3,371	3,321	0.1%	3,507 - 3,692	3,474	3.2%	3,703 - 4,059	3,774	1.9%
Maryland	4,463 - 4,551	4,279	5.0%	4,593 - 4,791	4,379	6.5%	4,719 - 5,064	4,519	7.1%
Wisconsin	2,223 - 2,288	2,395	-6.1%	2,442 - 2,569	2,739	-8.9%	2,646 - 2,926	3,114	-11.1%

**Table 6.** Summary of selected COVID-19 models including underlying methodologies, predicted features, spatial resolution, scenario analysis features, and frequency of data updates


Model Name	Institution	URL	Methodology	Predicted Features <sup>a</sup>	Spatial Resolution <sup>b</sup>	Scenario Analysis	Frequency of Data Updates
COVID Forecast Hub	University of Massachusetts-Amherst Reich Lab	<a href="https://covid19forecasthub.org/">https://covid19forecasthub.org/</a>	Ensemble method combining results from multiple models	C, D, H,	N, S, C	Selected individual models in the ensemble method include scenario analysis	Weekly
Auquan	CDC, Auquan Data Science	<a href="https://covid19-infection-model.auquan.com/">https://covid19-infection-model.auquan.com/</a>	Fitted SD model (SEIR)	C, D	G, N, S	Limited to selected model parameters (e.g., infection spread, social distancing)	Daily
Columbia	Columbia Mailman School of Public Health	<a href="https://cuepi.shinyapps.io/COVID-19/">https://cuepi.shinyapps.io/COVID-19/</a>	SD model (SEIR)	C, H	S, C	Limited to adjustments to the $R_0$ values	Daily
Columbia-UNC	Columbia University and UNC Chapel Hill	<a href="https://github.com/COVID19BIOSTAT/covid19_prediction">https://github.com/COVID19BIOSTAT/covid19_prediction</a>	Survival-convolution model	C, D	N	NA	NA
IHME	University of Washington - Institute for Health Metrics and Evaluation	<a href="https://covid19.healthdata.org/united-states-of-america?view=total-deaths&amp;tab=trend">https://covid19.healthdata.org/united-states-of-america?view=total-deaths&amp;tab=trend</a>	SD model (SEIR) calibrated using real-world data	C, D, H	G, N, S	Scenario analysis based on vaccination, mask use, and government-imposed mandates	Frequently
DDS	University of Texas at Austin UT	<a href="https://dds-covid19.github.io/index.html">https://dds-covid19.github.io/index.html</a>	Negative binomial linear dynamic system	C, D	N, S	NA	NA
Google-HSPH	Google Cloud AI	<a href="https://datastudio.google.com/c/reporting/52f6e744-66c6-47aa-83db-f74201a7c4df/page/EfwUB">https://datastudio.google.com/c/reporting/52f6e744-66c6-47aa-83db-f74201a7c4df/page/EfwUB</a>	Combination of SD model (SEIR) and covariates encoding within a computational graph framework	C, D, H	S, C	NA	Bi-weekly
ISU	Iowa State University	<a href="https://covid19.stat.iastate.edu/">https://covid19.stat.iastate.edu/</a>	Discrete-time spatial epidemic model	C, D	S, C	NA	Daily
JHU-APL	John Hopkins University Applied	<a href="https://buckymodel.com/">https://buckymodel.com/</a>	Spatially distributed SD models (SEIR) stratified based on age	C, D, H	S, C	NA	NA

Model Name	Institution	URL	Methodology	Predicted Features <sup>a</sup>	Spatial Resolution <sup>b</sup>	Scenario Analysis	Frequency of Data Updates
	Physics Laboratory LLC						
MIT-ORC	Massachusetts Institute of Technology Operations Research Center	<a href="https://www.covidanalytics.io/projections">https://www.covidanalytics.io/projections</a>	Adjusted SD model (SEIR)	C, D, H	G, N, S	NA	NA
Northeastern - MOBS	Northeastern University	<a href="https://covid19.gleamproject.org/">https://covid19.gleamproject.org/</a>	Adjusted SD model (SEIR) using a metapopulation approach and age-specific contact matrix	C, D, H	N, S	Scenario analysis based on different levels of social distancing	Weekly
Oliver Wyman	Oliver Wyman	<a href="https://pandemicnavigator.oliverwyman.com/">https://pandemicnavigator.oliverwyman.com/</a>	Extended SD model (SIR) including detected and undetected infected populations	C, D	G, N, S, C	Scenario analysis based on mobility and testing	Daily
UCLA	University of California LA	<a href="https://covid19.uclaml.org/">https://covid19.uclaml.org/</a>	Adjusted SD model (SEIR) accounting for unreported recovery	C, D	G, N, S	NA	Weekly
UCSB	University of California Santa Barbara	<a href="https://github.com/Gandor26/covid-open/">https://github.com/Gandor26/covid-open/</a>	Attention crossing time series	C	S	NA	Weekly
UGA - CEID	University of Georgia Center for the Ecology of Infectious Disease	<a href="https://github.com/cdcepi/COVID-19-Forecasts/blob/master/COVID-19_Forecast_Model_Descriptions.md#Aquan">https://github.com/cdcepi/COVID-19-Forecasts/blob/master/COVID-19_Forecast_Model_Descriptions.md#Aquan</a>	Statistical Random Walk Model	C, D	N, S, C	NA	Weekly
UT	University of Texas	<a href="https://covid-19.tacc.utexas.edu/projections/">https://covid-19.tacc.utexas.edu/projections/</a>	Ensemble of curve fitting and SD model (SEIR)	D	S	NA	Daily

<sup>a</sup> C: Case prediction; D: Death prediction; H: Hospitalization prediction


<sup>b</sup> G: Global-level predictions (i.e., different countries); N: National-level predictions; S: State-level predictions; C: County-level predictions

**Figure 1.** Overview of the multi-method community disease risk model (M<sup>2</sup>-CDRM) including key data layers, modeling framework, and model outputs




**Figure 2.** COVID-19 case projection comparison between state and county optimization for three localities in Virginia: (a) Richmond City; (b) Montgomery County; and (c) Norfolk City.


**(a) Richmond City**




**(b) Montgomery County**




**(c) Norfolk City**



**Figure 3.** Three-day rolling average of new COVID-19 cases per 100,000 residents estimated based on the mean estimated  $RE_t$  values for four localities in Virginia: (a) Charlottesville City, (b) Hampton City, (c) Portsmouth City, and (d) Spotsylvania County.




**Figure 4.** Three-day rolling average of new COVID-19 deaths based on the mean estimated  $RE_t$  values for four localities in Virginia: (a) Charlottesville City, (b) Hampton City, (c) Portsmouth City, and (d) Spotsylvania County.




**Figure 5.** Three-day average of new COVID-19 hospitalizations per 100,000 persons projections based on the mean estimated  $RE_t$  values for four localities in Virginia: (a) Charlottesville City, (b) Hampton City, (c) Portsmouth City, and (d) Spotsylvania County.


(a) Charlottesville City




(b) Hampton City




(c) Portsmouth City




(d) Spotsylvania County



**Figure 6.** COVID-19 ICU bed utilization projections based on the mean estimated  $RE_t$  values for four localities in Virginia: (a) Charlottesville City, (b) Hampton City, (c) Portsmouth City, and (d) Spotsylvania County



**Figure 7.** Aggregated risk scores for individual counties in Virginia.



# Figures






Figure 1

Overview of the multi-method community disease risk model (M2-CDRM) including key data layers, modeling framework, and model outputs




**Figure 2**

COVID-19 case projection comparison between state and county optimization for three localities in Virginia: (a) Richmond City; (b) Montgomery County; and (c) Norfolk City.



**Figure 3**


Three-day rolling average of new COVID-19 cases per 100,000 residents estimated based on the mean estimated  $RE_t$  values for four localities in Virginia: (a) Charlottesville City, (b) Hampton City, (c) Portsmouth City, and (d) Spotsylvania County.




**Figure 4**

Three-day rolling average of new COVID-19 deaths based on the mean estimated  $RE_t$  values for four localities in Virginia: (a) Charlottesville City, (b) Hampton City, (c) Portsmouth City, and (d) Spotsylvania County.


(a) Charlottesville City




(b) Hampton City



(c) Portsmouth City




(d) Spotsylvania County




**Figure 5**

Three-day average of new COVID-19 hospitalizations per 100,000 persons projections based on the mean estimated  $RE_t$  values for four localities in Virginia: (a) Charlottesville City, (b) Hampton City, (c) Portsmouth City, and (d) Spotsylvania County.


(a) Charlottesville City



(b) Hampton City



(c) Portsmouth City



(d) Spotsylvania County





Figure 6

COVID-19 ICU bed utilization projections based on the mean estimated  $RE_t$  values for four localities in Virginia: (a) Charlottesville City, (b) Hampton City, (c) Portsmouth City, and (d) Spotsylvania County



**Figure 7**

Aggregated risk scores for individual counties in Virginia.